Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Iranian president warns of retaliation against Gulf states - 2Figure out How to Ascertain the Restitution Time frame for Your Sunlight based chargers
- 3This St Nick Truly Can Advise How To Drink And Hack Your Headache
- 4Shredded cheese sold in dozens of states recalled due to potential for metal fragment contamination
- 5ONE returns to Red Sea with new service
- Vote in favor of your Number one Sort of Cap
- Australia Cracks Down on Gambling Ads as Prediction Markets Like Polymarket Remain Blocked
- Moon rush: These private spacecraft will attempt lunar landings in 2026
- The Best Cell phone Brands for Tech Aficionados
- 6 Financial plan 3D Printers with the Best Worth
- Recalled Super Greens diet supplement powder sickens 45 with salmonella
- Israel intensifies Lebanon attacks and hits areas not in Hezbollah's control
- Flying without a Real ID? That'll soon cost you $45, TSA says.
- Hamas Navy head, engineer of Khan Yunis tunnel network killed in Gaza, IDF confirms
